Product nameAnti-PON1 antibody [EPR2893]
See all PON1 primary antibodies
DescriptionRabbit monoclonal [EPR2893] to PON1
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: ICC or IHC-P
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human PON1 aa 100-200. The exact sequence is proprietary.
- Human fetal kidney, ovary cancer, fetal liver and plasma lysates.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
PurityTissue culture supernatant
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
Our Abpromise guarantee covers the use of ab126597 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Detects a band of approximately 40 kDa (predicted molecular weight: 40 kDa).|
|IP||1/10 - 1/100.|
FunctionHydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.
Tissue specificityPlasma, associated with HDL (at protein level). Expressed in liver, but not in heart, brain, placenta, lung, skeletal muscle, kidney or pancreas.
Involvement in diseaseGenetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5) [MIM:612633]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Note=Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients.
Sequence similaritiesBelongs to the paraoxonase family.
The signal sequence is not cleaved.
Present in two forms, form B contains a disulfide bond, form A does not.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
- A esterase 1 antibody
- A-esterase 1 antibody
- Aromatic esterase 1 antibody
All lanes : Anti-PON1 antibody [EPR2893] (ab126597) at 1/10000 dilution
Lane 1 : Fetal kidney lysate
Lane 2 : Ovary cancer lysate
Lane 3 : Fetal liver lysate
Lane 4 : Human plasma lysates
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 40 kDa
Observed band size: 40 kDa
This product has been referenced in:
- Li Y et al. Hepatic Forkhead Box Protein A3 Regulates ApoA-I (Apolipoprotein A-I) Expression, Cholesterol Efflux, and Atherogenesis. Arterioscler Thromb Vasc Biol 39:1574-1587 (2019). Read more (PubMed: 31291759) »
- Huang Y et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 123:3815-28 (2013). IP ; Human . Read more (PubMed: 23908111) »